The patient’s age at the time of the serum sample, ECOG performance status, presence of BM or subcutaneous metastases, number of previous metastatic CT lines, tumor biological subtype, high HER2 ECD, high CA 15–3 and high Tau serum levels were independently associated with poor prognosis (Table 3). This evidence concerns the gene MAPT and neoplasm.